FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114468318> ?p ?o ?g. }

• W2114468318 endingPage "642" @default.
• W2114468318 startingPage "634" @default.
• W2114468318 abstract "Abstract Purpose: Angiogenesis is required for tumor progression and represents a rational target for therapeutic intervention. Histone deacetylase (HDAC) inhibitors have been shown to have activity against various tumor cell types by inhibiting proliferation and inducing apoptosis both in vitro and in vivo. HDAC inhibitors have also been reported to inhibit angiogenesis. The goal of this study was to characterize the antiangiogenic and antitumor activity of a recently developed HDAC inhibitor, the hydroxamic derivative LBH589. Materials and Methods: To evaluate the antiangiogenesis activity of LBH589, we did cell cycle analysis, cell proliferation, tube formation, invasion assays in vitro, and Matrigel plug assay in vivo. To determine the antitumor activity of LBH589, we established human prostate carcinoma cell PC-3 xenografts in vivo. To evaluate the effect of LBH589 on endothelial signaling pathways, gene expression, and protein acetylation, we did Western blots and reverse transcription-PCR in human umbilical vein endothelial cells (HUVEC). Immunohistochemical analysis was done to evaluate new blood vessel formation in vivo. Results: LBH589 induced acetylation of histone H3 and α-tubulin protein in HUVECs. Histone and nonhistone protein acetylation correlated with induction of G2-M cell cycle arrest, inhibition of HUVEC proliferation, and viability. Noncytotoxic concentrations of LBH589 inhibited endothelial tube formation, Matrigel invasion, AKT, extracellular signal-regulated kinase 1/2 phosphorylation, and chemokine receptor CXCR4 expression. In vivo dosing of mice with LBH589 (10 mg/kg/d) reduced angiogenesis and PC-3 tumor growth. Conclusion: This study provides evidence that LBH589 induces a wide range of effects on endothelial cells that lead to inhibition of tumor angiogenesis. These results support the role of HDAC inhibitors as a therapeutic strategy to target both the tumor and endothelial compartment and warrant the clinical development of these agents in combination with angiogenesis inhibitors." @default.
• W2114468318 created "2016-06-24" @default.
• W2114468318 creator A5003107448 @default.
• W2114468318 creator A5022897881 @default.
• W2114468318 creator A5028510625 @default.
• W2114468318 creator A5029250422 @default.
• W2114468318 creator A5040429080 @default.
• W2114468318 creator A5049691904 @default.
• W2114468318 creator A5050431989 @default.
• W2114468318 creator A5054542626 @default.
• W2114468318 creator A5075489646 @default.
• W2114468318 date "2006-01-15" @default.
• W2114468318 modified "2023-10-16" @default.
• W2114468318 title "Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589" @default.
• W2114468318 cites W1587947784 @default.
• W2114468318 cites W1595810968 @default.
• W2114468318 cites W1783580437 @default.
• W2114468318 cites W1819301164 @default.
• W2114468318 cites W1966535797 @default.
• W2114468318 cites W1968972540 @default.
• W2114468318 cites W1971621147 @default.
• W2114468318 cites W1979832500 @default.
• W2114468318 cites W1981591956 @default.
• W2114468318 cites W2005975965 @default.
• W2114468318 cites W2007493092 @default.
• W2114468318 cites W2011810742 @default.
• W2114468318 cites W2023501346 @default.
• W2114468318 cites W2028466368 @default.
• W2114468318 cites W2030729823 @default.
• W2114468318 cites W2041265190 @default.
• W2114468318 cites W2048306047 @default.
• W2114468318 cites W2064959533 @default.
• W2114468318 cites W2074976119 @default.
• W2114468318 cites W2082391985 @default.
• W2114468318 cites W2090465622 @default.
• W2114468318 cites W2092118563 @default.
• W2114468318 cites W2095561162 @default.
• W2114468318 cites W2099959716 @default.
• W2114468318 cites W2101031694 @default.
• W2114468318 cites W2115354390 @default.
• W2114468318 cites W2135085078 @default.
• W2114468318 cites W2139354324 @default.
• W2114468318 cites W2148495272 @default.
• W2114468318 cites W2150341008 @default.
• W2114468318 cites W2153503145 @default.
• W2114468318 cites W2157228274 @default.
• W2114468318 cites W2157769714 @default.
• W2114468318 cites W2157899072 @default.
• W2114468318 cites W2161235995 @default.
• W2114468318 cites W2162934657 @default.
• W2114468318 cites W2163453798 @default.
• W2114468318 cites W2164380111 @default.
• W2114468318 cites W2167118090 @default.
• W2114468318 cites W2486272530 @default.
• W2114468318 cites W4240513782 @default.
• W2114468318 cites W4253705647 @default.
• W2114468318 doi "https://doi.org/10.1158/1078-0432.ccr-05-1132" @default.
• W2114468318 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16428510" @default.
• W2114468318 hasPublicationYear "2006" @default.
• W2114468318 type Work @default.
• W2114468318 sameAs 2114468318 @default.
• W2114468318 citedByCount "265" @default.
• W2114468318 countsByYear W21144683182012 @default.
• W2114468318 countsByYear W21144683182013 @default.
• W2114468318 countsByYear W21144683182014 @default.
• W2114468318 countsByYear W21144683182015 @default.
• W2114468318 countsByYear W21144683182016 @default.
• W2114468318 countsByYear W21144683182017 @default.
• W2114468318 countsByYear W21144683182018 @default.
• W2114468318 countsByYear W21144683182019 @default.
• W2114468318 countsByYear W21144683182020 @default.
• W2114468318 countsByYear W21144683182021 @default.
• W2114468318 countsByYear W21144683182022 @default.
• W2114468318 countsByYear W21144683182023 @default.
• W2114468318 crossrefType "journal-article" @default.
• W2114468318 hasAuthorship W2114468318A5003107448 @default.
• W2114468318 hasAuthorship W2114468318A5022897881 @default.
• W2114468318 hasAuthorship W2114468318A5028510625 @default.
• W2114468318 hasAuthorship W2114468318A5029250422 @default.
• W2114468318 hasAuthorship W2114468318A5040429080 @default.
• W2114468318 hasAuthorship W2114468318A5049691904 @default.
• W2114468318 hasAuthorship W2114468318A5050431989 @default.
• W2114468318 hasAuthorship W2114468318A5054542626 @default.
• W2114468318 hasAuthorship W2114468318A5075489646 @default.
• W2114468318 hasConcept C104317684 @default.
• W2114468318 hasConcept C119157956 @default.
• W2114468318 hasConcept C123012128 @default.
• W2114468318 hasConcept C153911025 @default.
• W2114468318 hasConcept C202751555 @default.
• W2114468318 hasConcept C2776056115 @default.
• W2114468318 hasConcept C2776202225 @default.
• W2114468318 hasConcept C2778305200 @default.
• W2114468318 hasConcept C2778608917 @default.
• W2114468318 hasConcept C2780394083 @default.
• W2114468318 hasConcept C502942594 @default.
• W2114468318 hasConcept C55493867 @default.
• W2114468318 hasConcept C64927066 @default.
• W2114468318 hasConcept C86803240 @default.

• next